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ABSTRACT
Objectives: To compare the incidence of perioperative
complications and postoperative healthcare utilization
and costs in laparoscopic supracervical hysterectomy
(LSH) versus laparoscopic-assisted vaginal hysterectomy
(LAVH) patients.
Methods: Women 18 years with LSH or LAVH were
extracted using a large national commercial claims data-
base from 1/1/2007 through 9/30/2008. Outcome was
perioperative complications and gynecologic-related
postoperative resource use and costs. Multivariate analysis
was performed to compare postsurgical outcomes be-
tween the cohorts.
Results: The final sample consisted of 6,198 LSH patients
and 14,181 LAVH patients. LSH patients were significantly
more likely to have dysfunctional uterine bleeding and
leiomyomas and less likely to have endometriosis and
prolapse as the primary diagnosis, and also significantly
more likely to have a uterus that weighed 250 grams
than LAVH patients. Compared with LAVH patients, LSH
patients had significantly lower overall infection rates
(7.4% versus 6.2%, P.002) and lower total gynecologic-
related postoperative costs ($252 versus $385, P.001,
within 30 days of follow-up and $350 versus $569,
P.001, within 180 days of follow-up). Significant cost
differences remained following multivariate adjustment
for patient characteristics.
Conclusions: LSH patients demonstrated fewer periop-
erative complications and lower GYN-related postopera-
tive costs compared to LAVH patients.
Key Words: Laparoscopic supracervical hysterectomy,
Laparoscopic-assisted vaginal hysterectomy, Gynecologic-
related healthcare utilization and costs, Perioperative com-
plications.
INTRODUCTION
Of major gynecologic surgical procedures, hysterectomy
is the most prevalent worldwide and is second only to
cesarean delivery in the United States (US).1,2 Over
600,000 women undergo hysterectomies each year in the
US, and approximately one-third of women will have had
the procedure performed by the age of 60 years.2,3,4 Hys-
terectomies can be performed using abdominal, vaginal,
or laparoscopic approaches, and given the estimated $5
billion in hospital charges resulting from this procedure
annually, the outcomes and costs associated with each
approach are important considerations.5
Choice of approach can be impacted by the indication for
hysterectomy, with abdominal hysterectomies often used
for gynecological cancers. Vaginal hysterectomies are
more commonly performed for prolapse or menstrual
disorders when the uterus is of normal or slightly enlarged
size.2,5,6 Laparoscopic hysterectomies include laparo-
scopic supracervical hysterectomy (LSH), laparoscopic-
assisted vaginal hysterectomy (LAVH), total laparoscopic
hysterectomy and da Vinci hysterectomy. Both the Amer-
ican College of Obstetrics and Gynecology (ACOG) and
the American Association of Gynecologic Laparoscopists
(AAGL) support minimally invasive alternatives to abdom-
inal hysterectomy, as these procedures are associated with
lower surgical risks, shorter lengths of stay, and quicker
return to normal activities than abdominal hysterectomy
is.7 Warren et al4 also found significant cost savings asso-
ciated with laparoscopic hysterectomy versus abdominal
hysterectomy.
Several studies have compared LSH to LAVH evaluating
operating time, blood loss, length of hospital stays, and
morbidity rates. Findings suggest more favorable out-
comes associated with LSH, although sample sizes were
small and differences were not always significant.8,9,10,11
The purpose of our study was to determine the incidence
of perioperative complications, postoperative healthcare
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SCIENTIFIC PAPERutilization, and costs in LSH versus LAVH patients, using a
large, commercially insured population.
METHODS
Data Source
Data were derived from the Thomson Reuters MarketScan
Commercial Claims and Encounter Database (Commercial
Database) from the time period July 1, 2006 through
March 31, 2009. The database is constructed from claims
and enrollment data provided by over 130 large employer-
sponsored health plans from across the US and is Health
Insurance Portability and Accountability Act (HIPAA)
compliant.
The Commercial Database contains the healthcare expe-
rience of privately insured individuals covered under a
variety of fee-for-service, fully capitated, and partially
capitated health plans. There were approximately 34.6
million covered lives in 2008. Utilization, outcomes, and
cost data are captured across the full continuum of care for
insurance reimbursable services delivered in all settings,
including physician office visits, emergency room (ER)
visits, hospital stays, and outpatient pharmacy claims. The
age and sex distribution of patients in MarketScan are
similar to that in the Medical Expenditure Panel Survey
(MEPS), which is a nationally representative database.
Patient Selection
Women with evidence of LSH or LAVH between January
1, 2007 and September 30, 2008 were selected into 2
cohorts based on hysterectomy type, with July through
December 2006 as the potential preperiod and October
2008 through March 2009 as the potential follow-up pe-
riod. LSH was determined by the presence of a claim with
any of the following codes: International Classification of
Diseases, Ninth Edition, Clinical Modification (ICD-9-CM)
procedure code 68.31, Current Procedural Terminology
(CPT) codes 58541 – 58544, and CPT code 58548. Codes
for LAVH included ICD-9-CM procedure code 68.51 and
CPT codes 58550, 58552, 58553, and 58554. The date of
the first LSH or LAVH procedure code in the selection
period was assigned as the index date. Where both an
ICD-9-CM procedure code and a CPT code indicating the
same procedure appeared for the same patient, the ICD-
9-CM procedure code in the inpatient setting was selected
as the index date. Patients were required to have 6 months
of continuous medical and prescription coverage prior to
the index date and 6 months subsequent to the index date.
The postindex period included the index date. Patients
were excluded if they were 18 years of age or if they had
a diagnosis of cancer in the pre- or postindex periods
(malignant neoplasms, ICD-9-CM diagnosis codes 140.xx
through 209.xx, and carcinoma in situ and neoplasms of
uncertain behavior, ICD-9-CM diagnosis codes 230.xx
through 239.xx). Patients were also excluded if they had
index date procedure codes for both LSH and LAVH (pos-
sibly due to coding errors) or if the length of stay (LOS)
associated with the index procedure exceeded 20 days
(based on the 99th percentile distribution of LOS).
Variables
A number of explanatory and outcome variables were
determined. (Diagnosis, procedure, and drug codes used
in their definition are available from the authors.)
Demographic variables were measured at index and in-
cluded age, insurance plan type, geographic region, and
urban versus rural residence. Clinical variables included
the primary diagnoses on the index procedure claim;
physician type on the index procedure claim; year of
hysterectomy; emergent presentation, defined as an ER
record associated with an inpatient admission for the
index LSH or LAVH; a flag for the inpatient setting for the
index LSH or LAVH; Charlson Comorbidity Index (CCI)
score, Deyo version, separately for the preindex period
and the index date, as well as counts by disease category;
specific conditions of interest occurring in the preindex
period and on index date based on both primary and
secondary diagnosis codes and procedure codes; pelvic or
abdominal surgeries occurring in the preindex period;
medications of interest occurring in the preindex period;
primary diagnosis on index date, and uterine weight at
index.
Outcome variables included perioperative outcomes and
gynecologic-related (GYN-related) postoperative resource
utilization and costs. The perioperative outcomes in-
cluded infection, procedure-specific complications, anal-
gesic use, inpatient mortality, and injury. The number and
percentage of patients with these outcomes were deter-
mined as were costs for claims containing diagnosis, pro-
cedure, and/or drug codes consistent with their definition
within the 30 days following and including the index date.
GYN-related postoperative outcomes included healthcare
resource utilization for inpatient, ER, and outpatient ser-
vice categories for claims containing codes consistent with
a GYN condition within the 30 days following the index
date or index admission discharge date and separately for
the 6 months following the index date or index admission
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sion itself). Diagnosis codes for GYN-related conditions
can be found in Appendix 1. The number and percentage
of patients, mean number of services, and costs were
reported.
The costs for claims processed under a fee-for-service
arrangement were the allowed charges (ie, the actual
amounts paid by primary and secondary insurers plus
patient cost share amounts [ie, copayments and deduct-
ibles]). The costs for claims processed under a capitated
arrangement were estimated using the average cost of
noncapitated claims, by procedure, geographic region,
and year. All costs were adjusted to 2008 dollars using the
medical service component of the Consumer Price Index
(CPI).
Analyses
Descriptive analysis was performed on study variables,
with counts and percentages reported for categorical vari-
ables and means (standard deviations [SDs]) reported for
continuous variables. Statistical tests of significance for
differences between the LSH and LAVH cohorts were
conducted, with chi-square tests used to evaluate differ-
ences for categorical variables and t tests for continuous
variables. Multivariate analysis was performed to compare
outcomes between the LSH and LAVH cohorts. Logistic
regression models were used to estimate the impact of
hysterectomy type on clinical outcomes and utilization,
with calculation of odds ratios (ORs), and generalized
linear models (GLM) were used to estimate the impact on
costs, with calculation of the marginal impact (ie, incre-
mental cost difference). All multivariate analysis con-
trolled for patients’ demographic characteristics, comorbid
conditions, evidence of surgery in the preperiod, uterine
weight, and diagnosis on the hysterectomy date.
RESULTS
A total of 13,551 and 31,232 women were selected with
LSH and LAVH, respectively, from January 1, 2007 through
September 30, 2008 (Table 1). Among them, 407 had
claims for both LSH and LAVH, and 3 had an LOS of 20
days. They were excluded from the study. After screening
for all inclusion and exclusion criteria, the final sample
consisted of 6,198 LSH patients and 14,181 LAVH patients.
Demographic Characteristics
Mean age was 43.2 and 43.5 years for the LSH and LAVH
cohorts, respectively (Table 2). A greater percentage of
younger and older women (18 to 24, 25 to 34, and 55 to 64
years) underwent LAVH, while the reverse was true for
middle-aged women (35 to 44 and 45 to 54 years) (P.05
for all). The majority of patients were covered under
health maintenance organization (HMO) and preferred
provider organization (PPO) plans, approximately 80%
from each cohort. Patients resided primarily in the South
(57.7% of LSH and 61.2% of LAVH patients), followed by
the North Central and West regions, and were in predom-
inantly urban areas (82.7% of LSH and 75.0% of LAVH
patients).
Clinical Characteristics
There was a low level of comorbidity in both cohorts, as
indicated by the CCI score (Table 3). The only significant
difference in individual comorbidities was in renal disease
in the preindex period, with a higher percentage of LAVH
Table 1.
Sample Attrition
Criteria LSH Patients LAVH Patients
N% N%
LSH or LAVH January 1, 2007 through September 30, 2008 13,551 31,232
Continuous enrollment for 6-month preindex period 9,080 67.0 20,639 66.1
Continuous enrollment for 6-month postindex period 7,643 56.4 17,396 55.7
18 years of age 7,637 56.4 17,389 55.7
No cancer diagnosis in study period 6,605 48.7 14,591 46.7
Only LSH OR LAVH at index 6,198 45.7 14,184 45.4
Index hospitalization 20 days 6,198 45.7 14,181 45.4
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were small, 1% in either cohort. Analgesic use occurred
in 46% to 48% of LSH and LAVH patients in the preindex
period, immunosuppressives in 16% to 17%, and antibiot-
ics in 11% to 12%. Endometriosis was diagnosed (in both
primary and secondary positions) in approximately 12%
of the LSH and LAVH cohorts in the preindex period and
in about 33% of the cohorts at index. In the preindex
period, adhesions were diagnosed in 2% of each cohort,
with all other conditions of interest occurring in 1% of
patients. At index procedure, adhesions were diagnosed
in 13.6% and 12.0% of the LSH and LAVH cohorts, respec-
tively, and pelvic inflammatory disease was found in
about 2% of each cohort. All other conditions of interest at
index occurred in 1% of patients. Surgery in the prein-
dex period was uncommon, with the most frequently
performed procedures being adhesiolysis and ovarian
cystectomy, occurring in 1% of LSH and LAVH patients.
A greater percentage of the LSH cohort had dysfunctional
uterine bleeding (32.6%) and leiomyomas (38.0%) as their
primary diagnosis compared to the LAVH cohort (27.9%
and 26.3%, respectively, P.001 for both) (Table 3).
Within the LAVH cohort, more patients had endometriosis
(10.4%) and prolapse (8.0%) as the primary diagnosis,
versus the LSH cohort (9.3%, P.008 and 1.5%, P.001,
Table 2.
Demographic Characteristics
Characteristic LSH Patients LAVH Patients P Value
N6,198 N14,181
N/Mean %/SD N/Mean %/SD
Age (years), Mean (SD) 43.2 6.5 43.5 7.8 .009
18–24 11 0.2 55 0.4 .015
25–34 575 9.3 1,785 12.6 .001
35–44 2,914 47.0 5,984 42.2 .001
45–54 2,461 39.7 5,223 36.8 .001
55–64 237 3.8 1,134 8.0 .001
Insurance Plan Type
Comprehensive 104 1.7 298 2.1 .046
Exclusive Provider Organization (EPO) 79 1.3 115 0.8 .002
Health Maintenance Organization (HMO) 1,237 20.0 2,575 18.2 .002
Point of Service (POS) 572 9.2 1,558 11.0 .001
Preferred Provider Organization (PPO) 3,798 61.3 8,829 62.3 .184
POS with Capitation 38 0.6 89 0.6 .904
Consumer Driven Health Plan (CDHP) 185 3.0 351 2.5 .036
Other 185 3.0 366 2.6 .102
Geographic Region
Northeast 471 7.6 550 3.9 .001
North Central 1,150 18.6 2,885 20.3 .003
South 3,576 57.7 8,684 61.2 .001
West 983 15.9 2,021 14.3 .003
Unknown 18 0.3 41 0.3 .987
Urban/Rural Residence
Urban 5,126 82.7 10,637 75.0 .001
Rural 1,072 17.3 3,544 25.0 .001
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Clinical Characteristics
Characteristic Pre-Index Period At Index
LSH Patients LSH Patients P-value LAVH Patients LAVH Patients P-Value
N6,198 N14,181 N6,198 N14,181
N/Mean %/SD N/Mean %/SD N/Mean %/SD N/Mean %/SD
Charlson Comorbidity Index
b
CCI Score 0.11 0.37 0.12 0.40 0.327 0.03 0.18 0.03 0.21 .101
Chronic pulmonary disease 276 4.5 652 4.6 0.649 65 1.0 170 1.2 .356
Rheumatologic disease 59 1.0 126 0.9 0.661 4 0.1 13 0.1 .537
Diabetes (mild/moderate) 221 3.6 504 3.6 0.967 92 1.5 207 1.5 .893
Renal disease 7 0.1 37 0.3 0.036 2 0.0 7 0.0 .593
Medication Use
GnRH agonists 220 3.5 314 2.2 0.001 N/A
a
Analgesics 2,961 47.8 6,485 45.7 0.007
Antibiotics 666 10.7 1,644 11.6 0.079
Immunosuppressives 985 15.9 2,348 16.6 0.238
Conditions of Interest
Adhesions (and adhesiolysis) 147 2.4 302 2.1 0.279 840 13.6 1,704 12.0 .002
Endometriosis 730 11.8 1,735 12.2 0.358 2,035 32.8 4,664 32.9 .938
Pelvic inflammatory disease 58 0.9 121 0.9 0.561 98 1.6 224 1.6 .993
Deep vein thrombosis 19 0.3 35 0.2 0.445 1 0.0 5 0.0 .464
Pulmonary embolism 8 0.1 19 0.1 0.929 3 0.0 5 0.0 .663
Inflammatory bowel disease 15 0.2 53 0.4 0.134 8 0.1 23 0.2 .577
Ulcerative colitis 7 0.1 34 0.2 0.063 1 0.0 7 0.0 .271
Crohn’s disease 8 0.1 21 0.1 0.74 7 0.1 17 0.1 .894
Surgeries
Adhesiolysis 62 1.0 132 0.9 0.638 N/A
a
Unilateral/bilateral adnexectomy 12 0.2 65 0.5 0.005
Myomectomy 4 0.1 5 0.0 0.36
Ruptured appendix 0 0.0 0 0.0 –
Ovarian cystectomy 53 0.9 162 1.1 0.065
Exploratory laparoscopy 13 0.2 44 0.3 0.211
Dialysis 1 0.0 4 0.0 0.613
Primary Diagnosis
Dysfunctional uterine bleeding N/A
a 2,020 32.6 3,961 27.9 .001
Leiomyomas 2,353 38.0 3,723 26.3 .001
Endometriosis 574 9.3 1,474 10.4 .008
Prolapse 90 1.5 1,141 8.0 .001
Adhesions 32 0.5 66 0.5 .629
Table 3 continued on next page.
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to have a uterus that weighed 250 grams (16.4%), com-
pared to LAVH patients (10.3%, P.001). Physician spe-
cialty at index for over 75% of each cohort was obstetrics
and gynecology (data not reported in table). LAVH pa-
tients were significantly more likely to have their proce-
dures performed in the inpatient setting than LSH patients
(49.5% versus 36.6%, P.001) (data not reported in table).
Less than 1% of LSH and LAVH patients had their inpatient
procedure performed following an ER visit (data not re-
ported in table).
Index and Perioperative Outcomes and Costs
LAVH patients had significantly higher overall infection
rates compared to LSH patients (7.4% versus 6.2%,
P.002) primarily due to increased urinary tract infections
(4.1% versus 3.0%, P.001) (Table 4). Analgesic use was
also higher in LAVH patients (79.4% versus 75.3%,
P.001), driven by opiate use (76.5% versus 72.0%,
P.001). While costs associated with analgesic use were
greater in the LAVH patients (P.03), no other significant
cost differences were found in the indexing event or in
perioperative outcomes of interest.
GYN-Related Postoperative Resource Use and Costs
The percentage of patients with an inpatient readmis-
sion after the index procedure was significantly lower
in the LSH cohort than in the LAVH cohort (1.9% versus
3.3%, P.001, within 30 days of follow-up and 2.4%
versus 3.8%, P.001, within 180 days of follow-up)
(Table 5). While LOS for these postoperative inpatient
admissions was longer in the LSH than the LAVH cohort
(P.001 for both follow-up periods), the difference was
small in magnitude (0.15 to 0.16 days). The percentage
of patients with an ICU stay was also lower in the LSH
versus LAVH cohorts (P.001 for both follow-up peri-
ods). LSH patients had a significantly lower mean num-
ber of GYN-related outpatient office visits in both the
30-day and 180-day follow-up periods (P.001 for
both), driven primarily by a lower mean number of
primary care visits. Overall, LSH patients had signifi-
cantly lower total GYN-related costs ($252 versus $385,
P.001, within 30 days of follow-up and $350 versus
$569, P.001, within 180 days of follow-up).
Multivariate Regression Results
The LSH cohort had a significantly lower risk of infection
compared to the LAVH cohort (OR 0.830, P.004) (Table 6).
Significant differences in favor of LSH were also found
for hematologic complications and analgesic use. For
both the 30-day and 180-day follow-up periods, the LSH
cohort had significantly lower risks of GYN-related in-
patient readmissions, ER visits, and outpatient office
visits. The total GYN-related postoperative costs were
Table 3. (continued)
Clinical Characteristics
Characteristic Pre-Index Period At Index
LSH Patients LSH Patients P-value LAVH Patients LAVH Patients P-Value
N6,198 N14,181 N6,198 N14,181
N/Mean %/SD N/Mean %/SD N/Mean %/SD N/Mean %/SD
Other 1,129 18.2 3,816 26.9 .001
Year of Hysterectomy
2007 N/A
a 3,271 52.8 8,278 58.4 .001
2008 2,927 47.2 5,903 41.6 .001
Uterine Weight
250 grams N/A
a 4,940 79.7 12,548 88.5 .001
250 grams 1,019 16.4 1,466 10.3 .001
Not specified 239 3.9 167 1.2 .001
N/Anot applicable, ie, characteristic not measured in period.
bValues were reported for mean CCI score and for counts of individual diseases used in score. Individual disease counts were reported
for diseases where at least 1% of patients had disease in either the preperiod or at index or where P-value was significant at .05.
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Index and Perioperative Outcomes: Occurrence and Costs During Index Procedure and in 30-Day Follow-up Period
Outcome LSH Patients LAVH Patients P-Value
N6,198 N14,181
N/Mean %/SD N/Mean %/SD
Occurrence of:
Infection 383 6.2 1,046 7.4 .002
Acute lymphadenitis 0 0.0 1 0.0 .509
Cellulitis/skin abscesses 37 0.6 90 0.6 .753
Infection of colostomy or enterostomy 0 0.0 0 0.0 –
Intra-abdominal abscess or suppurative peritonitis 14 0.2 34 0.2 .851
Local skin infections 9 0.1 12 0.1 .215
Pelvic organ infection 119 1.9 294 2.1 .475
Posttraumatic wound infection 1 0.0 2 0.0 .912
Pulmonary infection 45 0.7 107 0.8 .828
Rectal abscess 0 0.0 1 0.0 .509
Retroperitoneal infection 1 0.0 2 0.0 .912
Sepsis 8 0.1 18 0.1 .969
Urinary tract infection 186 3.0 582 4.1 .001
Antibiotics initiated 3 days after index date 220 3.5 562 4.0 .157
Days of antibiotic use 6.35 3.67 6.88 5.67 .165
Procedure-specific Complications 1,364 22.0 3,255 23.0 .138
Pulmonary 182 2.9 457 3.2 .281
Cardiac 12 0.2 25 0.2 .789
Vascular/thromboembolic 25 0.4 59 0.4 .896
Shock 3 0.0 4 0.0 .474
Neurological 7 0.1 13 0.1 .656
Gastrointestinal tract 396 6.4 878 6.2 .592
Genitourinary 653 10.5 1,473 10.4 .75
Hematologic 152 2.5 476 3.4 .001
Vaginal dehiscence (same day) 1 0.0 15 0.1 .036
Vaginal dehiscence (within 30 days) 1 0.0 15 0.1 .036
Incisional hernia 21 0.3 25 0.2 .025
Trachelectomy 5 0.1 3 0.0 .048
Other 203 3.3 602 4.2 .001
Analgesic Use 4,670 75.3 11,255 79.4 .001
Opiate 4,460 72.0 10,849 76.5 .001
Non-opiate 2,141 34.5 4,974 35.1 .464
Inpatient Mortality 0 0.0 0 0.0 –
Injury 33 0.5 110 0.8 .056
Table 4 continued on next page.
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LAVH cohort in the 30-day and 180-day follow-up pe-
riods, respectively (P.001 for both).
DISCUSSION
The current study found distinct differences between the
LSH and LAVH cohorts. LSH patients were more likely to
have a hysterectomy due to dysfunctional uterine bleeding
and leiomyomas and less likely to undergo the procedure
due to endometriosis and prolapse. Unadjusted analyses
showed lower rates of overall infection and procedure-spe-
cific complications in LSH patients. Compared to LAVH pa-
tients, LSH patients had a lower number of GYN-related
outpatient office visits and lower total GYN-related costs in
both the 30-day and 180-day follow-up periods. Adjusted
analyses found significant differences in favor of LSH with
regard to the occurrence of overall infection, hematologic
complication, and analgesic use despite the fact that LSH
patients were also more likely than LAVH patients to have a
uterus that weighed 250 grams.
The marginal impact on costs was also in favor of LSH,
with $108 and $174 less in incurred total GYN-related
costs in the 30-day and 180-day follow-up periods,
respectively. Wu et al12 estimated that 538,722 hyster-
ectomies for benign disease were performed in 2003,
and 11.2% of them were done through the laparoscopic
route, which suggests a total of 60,337 laparoscopic
hysterectomies. If we assume 40% of these laparoscopic
hysterectomies were performed using the LSH proce-
dure rather than the LAVH procedure, the cost savings
would be $2.6 million and $4.2 million in the 30-day
and 180-day follow-up periods, respectively.
These results, while consistent with much of the previ-
ous work comparing LSH and LAVH, are important in
that the size of the study cohorts allowed for a robust
comparison of the 2 procedures using a diverse, com-
mercially insured population, and thus add further sup-
port to the existing evidence demonstrating improved
outcomes and fewer costs with LSH. The study by Milad
et al8 was a cohort analysis of 132 patients, 27 under-
going LSH and 105 undergoing LAVH, from a university
based medical center. Lalonde et al9 performed an of-
fice and hospital chart review and conducted a postop-
erative questionnaire on 40 patients, equally divided
between LSH and LAVH patients, from a private gyne-
cology practice and private hospital. El-Mowafi et al10
studied 259 patients, 123 with LSH and 136 with LAVH,
from US and non-US sites.
Hospital stays for LSH patients compared to LAVH pa-
tients were significantly shorter in Milad et al8 and
Lalonde et al9 and showed no difference in El-Mowafi et
al.10 Though our study did not examine the LOS for the
index procedure, LAVH patients were significantly
more likely to have their procedures performed in the
inpatient setting. Hysterectomy costs were significantly
less for LSH versus LAVH patients in both Milad et al8
and Lalonde et al9 but showed no difference in our
study. However, hysterectomy costs in Milad et al8 and
Lalonde et al9 were calculated from hospital costs,
while costs in our study were calculated from both
inpatient and outpatient costs, depending on where the
hysterectomy was performed. Further work is needed
to evaluate cost differences based on setting of care.
Though defined differently, the current study as well as
the 3 previous studies (Milad et al,8 Lalonde et al,9 and
El-Mowafi et al10) found fewer complications in the LSH
patients. The current study also found significantly lower
Table 4. (continued)
Index and Perioperative Outcomes: Occurrence and Costs During Index Procedure and in 30-Day Follow-up Period
Outcome LSH Patients LAVH Patients P-Value
N6,198 N14,181
N/Mean %/SD N/Mean %/SD
Costs of:
Infection $267 $2,616 $396 $8,017 .21
Procedure-specific Complications $1,280 $10,455 $1,154 $5,699 .27
Analgesic Use $14 $50 $15 $36 .03
Index Event $10,498 $10,285 $10,583 $9,167 .56
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tients.
In addition to the commonly recognized constraints of ad-
ministrative claims data,13 limitations specific to this study
should be noted when interpreting the results. First, selection
of LSH versus LAVH patients was based on the occurrence of
specific procedure codes in the claims history and thus is
dependent on the accuracy of these codes. However, be-
cause these are distinct surgeries and because we excluded
patients with both types of codes, we would expect any
misclassification to be small. Second, although we attempted
to control for confounding variables in the multivariate re-
gression analyses, other factors not captured in administra-
tive claims data, such as information on level of experience
of the surgeon or information on other patient factors that
drive surgeon preference for LSH versus LAVH, may have
impacted results. Finally, the study population comprised
commercially insured patients covered with large employers,
thus results may not be representative of all patients with
hysterectomy in the US, especially the uninsured or those
covered by Medicaid. In addition, more than half of the study
population lived in the South. and the regional distribution of
the study sample does not represent the regional distribution
of the US.
Table 5.
GYN-related Resource Utilization and Costs in 30-Day and 180-Day Follow-up Periods
Outcome 30-day Follow-up Period 180-day Follow-up Period
LSH Patients LAVH Patients P-value LSH Patients LAVH Patients P-value
N6,198 N14,181 N6,198 N14,181
N/Mean %/SD N/Mean %/SD N/Mean %/SD N/Mean %/SD
Utilization by Service Category:
a
Inpatient admissions
Patient had admission 119 1.9% 461 3.3% .001 149 2.4% 545 3.8% .001
# of admissions 0.02 0.14 0.03 0.19 .001 0.03 0.17 0.04 0.22 .001
Length of stay (days) 2.70 2.67 2.54 2.74 .001 2.57 2.55 2.42 2.54 .001
ICU stay 3 0.0% 11 0.1% .001 4 0.1% 18 0.1% .001
Re-admission rate
b 1 0.04% 7 0.10% .429 2 0.09% 25 0.35% .038
ER visits
Patient had ER visit 67 1.1% 235 1.7% .095 115 1.9% 340 2.4% .123
# of ER visits 0.020 0.267 0.029 0.267 .355 0.041 0.557 0.045 0.352 .268
Outpatient visits and services
# of office visits 0.068 0.484 0.086 0.424 .001 0.293 1.156 0.361 1.427 .001
# of primary care visits 0.055 0.465 0.068 0.359 .001 0.217 0.972 0.262 1.088 .001
# specialty visits 0.010 0.120 0.017 0.215 .018 0.060 0.350 0.084 0.715 .009
# of other office visits 0.002 0.067 0.002 0.059 .001 0.015 0.463 0.014 0.528 .99
# of outpatient services 0.222 0.937 0.267 1.010 .001 0.516 1.767 0.623 1.997 .001
Costs by Service Category:
a
Total $252 $1,594 $385 $2,720 .001 $350 $2,056 $569 $4,509 .001
Inpatient $138 $1,471 $270 $2,645 .001 $189 $1,870 $387 $4,372 .001
ER $5 $75 $6 $66 .137 $8 $88 $10 $96 .126
Outpatient visits and services $109 $527 $108 $581 .001 $153 $628 $171 $758 .001
aGYN-related utilization and costs were identified using all claims with a primary or secondary non rule-out diagnosis containing codes
consistent with GYN-related medical care.
bRe-admission rate is reported only for patients whose procedure was performed in the inpatient setting.
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LSH patients demonstrated fewer perioperative compli-
cations and lower GYN-related postoperative costs
compared to LAVH patients. Additional comparison of
these 2 laparoscopic approaches to hysterectomy is
needed to further clarify the clinical and cost effective-
ness of each procedure.
Table 6.
Impact of LSH Versus LAVH on Outcomes: Multivariate Regression Results
a
Outcome Length of Follow-up
Period (Days)
Measure P Value
Odds Ratio or Marginal Impact ($)
Peri-operative Outcomes
Presence of:
Infection 30 0.830 .004
Pelvic organ infection 30 0.903 .366
Procedure-specific complications 30 0.947 .152
Pulmonary complication 30 0.888 .195
Gastrointestinal tract complication 30 1.017 .795
Genitourinary complication 30 1.060 .261
Hematologic complication 30 0.667 .001
Analgesic use 30 0.812 .001
Costs of:
Infection 30 -$62.5 .145
Procedure-specific complications 30 $93.4 .340
Analgesic use 30 -$1.1 .019
Sum of the costs above 30 $43.6 .725
GYN-related Outcomes
Presence of:
Inpatient admission 30 0.610 .001
180 0.640 .001
ER visit 30 0.649 .003
180 0.782 .028
Physician office visit 30 0.764 .001
180 0.847 .001
Costs of:
Total 30 -$108 .001
180 -$174 .001
Inpatient 30 -$121 .001
180 -$172 .001
Outpatient (including ER) 30 $8 .365
180 -$8 .474
Outpatient (excluding ER) 30 $10 .245
180 -$6 .591
a ReferenceLAVH for all models.
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Appendix 1.
ICD-9-CM Diagnosis Codes for GYN-Related Conditions
ICD-9-CM
Diagnosis
Code
Description
593.3x Stricture or kinking of ureter
593.4x Other ureteric obstruction
593.82 Other specified disorders of kidney and ureter:
Ureteral fistula
593.89 Other specified disorders of kidney and ureter:
Other
595.xx Cystitis
599.0x Urethral stricture due to infection
599.6x Urinary obstruction, unspecified
614.xx Inflammatory disease of ovary, fallopian tube,
pelvic cellular tissue, and peritoneum
616.xx Inflammatory disease of cervix, vagina, and vulva
617.xx Endometriosis
618.xx Genital prolapse
619.xx Fistula involving female genital tract
620.6x Broad ligament laceration syndrome
620.7x Hematoma of broad ligament
622.xx Noninflammatory disorders of cervix
623.2x Stricture or atresia of vagina
623.4x Old vaginal laceration
623.6x Vaginal hematoma
625.xx Pain and other symptoms associated with female
genital organs
629.0x Hematocele, female, not elsewhere classified
867.xx Injury to pelvic organs
868.xx Injury to other intra-abdominal organs
902.xx Injury to blood vessels of abdomen and pelvis
996.xx Complications peculiar to certain specified
procedures
998.xx Other complications of procedures, NEC
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